SVS.V - Solarvest BioEnergy Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.1700
-0.0100 (-5.56%)
At close: 2:48PM EDT
Stock chart is not supported by your current browser
Previous Close0.1800
Open0.1700
Bid0.1700 x N/A
Ask0.1800 x N/A
Day's Range0.1700 - 0.1700
52 Week Range0.1500 - 0.3500
Volume3,000
Avg. Volume8,770
Market Cap5.832M
Beta (3Y Monthly)-0.23
PE Ratio (TTM)N/A
EPS (TTM)-0.0550
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Imagine Owning Solarvest BioEnergy (CVE:SVS) And Wondering If The 28% Share Price Slide Is Justified
    Simply Wall St.2 months ago

    Imagine Owning Solarvest BioEnergy (CVE:SVS) And Wondering If The 28% Share Price Slide Is Justified

    For many, the main point of investing is to generate higher returns than the overall market. But the main game is to...

  • FSD Pharma Announces Research Agreement with Solarvest to Develop Algae-based, Pharma-grade Cannabinoids
    CNW Group3 months ago

    FSD Pharma Announces Research Agreement with Solarvest to Develop Algae-based, Pharma-grade Cannabinoids

    TORONTO, May 7, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTC:FSDDF - News) (FRA: 0K9) ("FSD Pharma" or "FSD") and Solarvest BioEnergy Inc. (TSX-V:SVS.V - News) ("Solarvest"), a technology company that developed an algal-based flexible production platform capable of producing health products, announced today that they signed a definitive collaborative research and development agreement. Under the agreement, Solarvest will conduct research using its algal expression technology to develop pharmaceutical-grade cannabinoids. FSD Pharma and Solarvest have made investments into one another and FSD has the option to enter into an exclusive license arrangement over a subset of the project and receive royalty rights over all of the products that result from the project.

  • FSD Pharma Announces Signing of LOI with Solarvest to Develop and Test Pharma-Grade Cannabinoids out of Algae
    CNW Group6 months ago

    FSD Pharma Announces Signing of LOI with Solarvest to Develop and Test Pharma-Grade Cannabinoids out of Algae

    TORONTO, Feb. 5, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) ("FSD Pharma") and Solarvest BioEnergy Inc. (TSX-V:SVS.V - News) ("Solarvest") (collectively, the "Parties"), a technology company which has developed an algal-based flexible production platform capable of producing health products, are pleased to announce that they have signed a non-binding letter of intent ("LOI"). The parties intend to enter into a definitive agreement (the "Collaborative Research Agreement"), under which Solarvest would conduct research using its algal expression technology to develop pharma-grade cannabinoids (the "Project Cannabinoids"), the Parties would make mutual investments into one another, and Solarvest would grant FSD Pharma an exclusive license over a subset of the Project Cannabinoids and certain royalty rights over all of the other Project Cannabinoids.